


# INVITATION

## 4 October 2024

# Cutaneous T-Cell Lymphoma Management: An update

hotel Voco, Riyadh, Saudi Arabia



This information is intended for healthcare professionals in Middle-East and North-Africa (MENA) region

## Agenda

**Time: 13:00 – 18:00**

- 
- |               |   |
|---------------|---|
| 13:00         | <b>Welcome Lunch</b>  |
| 14:00 – 14:05 | <b>Welcome and introduction</b><br>Mr. Wassef El Mouhtar, Mealis, UAE   |
| 14:05 – 14:30 | <b>Clinical presentations and diagnosis of early stages</b><br>Dr. Alfadel Alshibani, King Faisal Specialist Hospital-Riyad, Saudi Arabia |
| 14:30 – 15:00 | <b>Clinical presentations and diagnosis of late stages</b><br>Prof. Julia Scarisbrick, Birmingham University Hospital, UK                 |
| 15:00 – 15:30 | <b>Interactive clinical cases</b><br>All  |
| 15:30 – 15:45 | <b>Coffee break</b>   |
| 15:45 – 16:15 | <b>Skin-directed therapies</b><br>Dr. Yousef Binamer, King Faisal Specialist Hospital-Riyad, Saudi Arabia                                 |
| 16:15 – 16:45 | <b>Systemic therapies</b><br>Dr. Alfadel Alshibani, King Faisal Specialist Hospital-Riyad, Saudi Arabia                                   |
| 16:45 – 17:15 | <b>A focus on ECP – current clinical guidelines and updates</b><br>Prof. Julia Scarisbrick, Birmingham University Hospital, UK            |
| 17:15 – 17:45 | <b>Therakos ECP – treatment overview</b><br>Mr. Daniel Riman, Mealis, UAE   |
| 17:45 – 18:00 | <b>Interactive discussion</b><br>All  |

*ECP: Extracorporeal Photopheresis*

*All speakers are subject to contract.*

*This is a medical programme run by Mealis Tamer in collaboration with Therakos (UK) Ltd*

[Privacy policy](#)



Follow the  
Therakos Institute



For more information on THERAKOS ECP Immunomodulation™ please visit [www.therakos.eu](http://www.therakos.eu)  
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.  
© 2024 Mallinckrodt. ME-2400004 July 2024.

*Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.*